Welcome to our dedicated page for Bausch + Lomb news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb stock.
Bausch + Lomb Corporation reports developments across its global eye health business, including vision care, surgical devices and ophthalmic pharmaceuticals. Recurring updates cover contact lenses and lens care products, eye vitamins and redness-relief drops, dry eye and prescription ophthalmology brands, intraocular lenses, vitrectomy cutters and the Stellaris Elite Vision Enhancement System.
Company news also includes financial results and guidance, scientific presentations, R&D pipeline discussions, FDA 510(k) clearances, European product launches and sustainability programs such as ONE by ONE Recycling. Product-specific coverage frequently references Biotrue, LUMIFY, XIIDRA, MIEBO, PreserVision, INFUSE, ULTRA ONE DAY, enVista and Bi-Blade technologies.
Bausch + Lomb (NYSE/TSX: BLCO) announced the U.S. launch of the EyeGility Inserter, a preloaded intraocular lens (IOL) delivery system designed for the enVista Aspire and Envy IOL families. EyeGility offers one-handed operation, balanced push force for smooth IOL delivery and a silicone soft-tipped plunger, allowing injection through a 2.4 mm incision and up to 20 minutes of standby time from preparation to lens delivery.
According to the company, EyeGility is now available in the U.S. with enVista Aspire preloaded IOLs, with enVista Envy lenses preloaded into EyeGility expected in the coming months. The release details indications, precautions, warnings and potential adverse events for the EyeGility inserter, enVista Aspire hydrophobic acrylic IOL and enVista Envy non-toric and toric hydrophobic acrylic IOLs, emphasizing physician judgment, patient selection and adherence to Directions for Use and federal law restrictions.
Bausch + Lomb (NYSE/TSX: BLCO) reported topline Phase 2 results for glaucoma candidate BL1107. The 159-patient study did not meet its primary visual field endpoint or key visual function secondary endpoints after 28 days of topical dosing.
The company will discontinue BL1107 as a glaucoma eye drop and concentrate on developing a sustained-release implant for geographic atrophy, with clinical trials expected in 2028. According to Bausch + Lomb, BL1107 showed intraocular pressure reduction and a safety profile consistent with prior experience. The firm highlights a diversified pipeline of more than 60 assets with multiple anticipated milestones across Consumer, Pharmaceuticals, Surgical and Vision Care segments.
Bausch + Lomb (NYSE/TSX: BLCO) launched Orphia, an AI-powered digital health platform designed to reduce operational burdens so eye care providers can focus more on patient care. The brand-agnostic platform’s first application supports pre-surgery cataract education and integrates with existing practice systems.
Orphia is developed with voice AI partner Hippocratic AI and will operate within Bausch + Lomb’s new Digital Health Services platform, led by Manisha Narasimhan, PhD, with plans to expand across the full ophthalmology patient journey over time.
Bausch + Lomb (NYSE:BLCO) will release its Q2 2026 financial results on Wednesday, July 29, 2026. Management will host a conference call and live webcast at 8 a.m. ET to discuss results and provide a business update.
Materials will be available in the Investor Relations section of the company website before the call.
Bausch + Lomb (NYSE/TSX: BLCO) reported new data from its third annual State of Dry Eye survey of 1,000 treated dry eye sufferers, highlighting emotional and quality-of-life impacts.
Findings link symptom relief with improved self-confidence, emotional wellbeing, productivity and mood, and reveal low awareness of links to hormonal and autoimmune conditions.
Bausch + Lomb (NYSE:BLCO) announced the U.S. launch of Blink Triple Care Preservative Free lubricant eye drops, a multi-dose, preservative-free version of the existing Blink Triple Care formula.
The lipid- and water-based drops use a natural oil and hyaluronate to create a dual-action moisture seal, offering 3‑in‑1 extended relief and up to 10 hours of dry eye symptom relief. The product is expected to be available at most major U.S. retailers and online, including Amazon, CVS, Target and Walgreens, by the end of June 2026.
Bausch + Lomb (NYSE:BLCO) announced that Chairman and CEO Brent Saunders and Chief Medical Officer and Head of R&D Yehia Hashad will join a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 9, 2026, at 1:20 p.m. ET. A live webcast will be accessible via the company’s investor relations website.
Bausch + Lomb (NYSE/TSX: BLCO) reported results of its 2026 annual meeting of shareholders held May 20, 2026. Shareholders elected 10 nominated directors, with each receiving over 331 million votes in favor and about 4.2–4.3 million against, plus broker non-votes.
Shareholders also approved, on a non-binding advisory basis, the compensation of named executive officers and appointed PricewaterhouseCoopers LLP as independent registered public accounting firm until the close of the 2027 annual meeting. Final vote tabulations will be filed on Form 8-K and posted on SEDAR+ and the company website.
Bausch + Lomb (NYSE:BLCO) launched PreserVision AREDS3 eye vitamins in the U.S. The formula combines clinically proven AREDS2 nutrients recommended by the NEI with a unique B‑vitamin complex to support macular health and help reduce the risk of moderate‑to‑advanced AMD progression.*
The triple‑action formula is designed to protect, nourish and boost macular health and is now available at most major retailers nationwide.
Bausch + Lomb (NYSE: BLCO) launched the Bi-Blade+ dual-port vitrectomy cutter in Europe for use with the Stellaris Elite vision enhancement system on May 7, 2026. Bi-Blade+ offers a 25,000 cpm cutting speed and a reported 25% average flow increase versus Bi-Blade, with a 62% reduction in cutter vibration and a 62% reduction in average infusion pressure when used with Adaptive Fluidics. The device is indicated for anterior and posterior vitrectomy, is compatible only with Stellaris Elite systems having Bi-Blade+ procedure pack compatibility, and includes standard surgical risks; users should consult Instructions for Use for full safety details.